Search Results for "block"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for block. Results 191 to 200 of 328 total matches.

Second-Generation Antipsychotics - Aripiprazole Revisited

   
The Medical Letter on Drugs and Therapeutics • Oct 10, 2005  (Issue 1219)
, it blocks serotonin 2A (5-HT 2A ) receptors and, like ziprasidone, stimulates the 5-HT 1A receptor ...
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a second-generation (atypical) antipsychotic drug, was approved by the FDA in 2002 for treatment of schizophrenia and more recently for bipolar disorder as well. It has been promoted as causing fewer adverse effects than other antipsychotics, without sacrificing efficacy.
Med Lett Drugs Ther. 2005 Oct 10;47(1219):81-2 |  Show IntroductionHide Introduction

Etravirine (Intelence) for HIV Infection

   
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008  (Issue 1288)
and other antiretroviral agents. 1 MECHANISM OF ACTION — Etravirine binds directly to reverse transcriptase and blocks ...
Etravirine (Intelence - Tibotec), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), has received fast-track FDA approval for use in combination therapy in treatment-experienced adults who have HIV-1 infection resistant to an NNRTI and other antiretroviral agents.
Med Lett Drugs Ther. 2008 Jun 16;50(1288):47-8 |  Show IntroductionHide Introduction

Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2013  (Issue 1418)
– Gilenya Transaminase elevations, bradycardia, C 0.5 mg PO once daily 60,423.00 (Novartis) AV block ...
The FDA has approved dimethyl fumarate (Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years for this indication.
Med Lett Drugs Ther. 2013 Jun 10;55(1418):45-7 |  Show IntroductionHide Introduction

Vedolizumab (Entyvio) for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014  (Issue 1451)
natalizumab, which blocks lymphocyte migration in the brain and gut by inhibiting 4β1 and 4β7 integrins ...
The FDA has approved vedolizumab (Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to, lost response to, or cannot tolerate standard treatment. Natalizumab (Tysabri), another integrin receptor antagonist, has been available for several years for treatment of Crohn's disease and multiple sclerosis.
Med Lett Drugs Ther. 2014 Sep 15;56(1451):86-8 |  Show IntroductionHide Introduction

Tavaborole Topical Solution (Kerydin) for Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015  (Issue 1463)
PHARMACOLOGY — Tavaborole blocks fungal protein synthesis by inhibiting aminoacyl-transfer ribonucleic acid ...
The FDA has approved tavaborole 5% solution (Kerydin – Anacor Pharmaceuticals) for topical treatment of toenail onychomycosis due to Trichophyton rubrum or Trichophyton mentagrophytes. It is the first oxaborole antifungal drug to be approved for this indication.
Med Lett Drugs Ther. 2015 Mar 2;57(1463):35 |  Show IntroductionHide Introduction

Idelalisib (Zydelig) for Chronic Lymphocytic Leukemia and Non-Hodgkins Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • May 11, 2015  (Issue 1468)
proliferation of malignant B-cells and primary tumor cells and inducing apoptosis. Blocking PI3Kδ inhibits ...
The FDA has approved idelalisib (Zydelig – Gilead), an oral kinase inhibitor, for use in combination with rituximab (Rituxan) for treatment of relapsed chronic lymphocytic leukemia (CLL). It is also approved as monotherapy for treatment of relapsed follicular lymphoma and relapsed small lymphocytic lymphoma (both are subtypes of indolent non-Hodgkins lymphoma) in patients who have received at least two prior systemic therapies.
Med Lett Drugs Ther. 2015 May 11;57(1468):74-5 |  Show IntroductionHide Introduction

In Brief: Two Drugs for Soft-Tissue Sarcoma (online only)

   
The Medical Letter on Drugs and Therapeutics • May 09, 2016  (Issue 1494)
transcription and blocks DNA repair proteins to achieve an antiproliferative effect.2 It has not been shown ...
The anthracycline doxorubicin with or without the alkylating agent ifosfamide is the standard first-line treatment for advanced soft-tissue sarcomas. The FDA recently approved the minor groove DNA intercalator trabectedin (Yondelis – Janssen) for treatment of unresectable or metastatic liposarcoma or leiomyosarcoma in patients previously treated with an anthracycline. Trabectedin has been available for years in Europe for treatment of advanced soft-tissue sarcoma. The FDA has also approved the microtubule inhibitor eribulin mesylate (Halaven – Eisai), which was approved earlier for...
Med Lett Drugs Ther. 2016 May 9;58(1494):e62 |  Show IntroductionHide Introduction

Reslizumab (Cinqair) for Severe Eosinophilic Asthma

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016  (Issue 1497)
, and activation of eosinophils. Reslizumab binds to IL-5, blocking its binding to IL-5 receptors on the surface ...
The FDA has approved reslizumab (Cinqair – Teva), a humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for add-on maintenance treatment of severe asthma in adults who have an eosinophilic phenotype. It is the second IL-5 antagonist to be approved in the US; mepolizumab (Nucala) was approved for the same indication in 2015.
Med Lett Drugs Ther. 2016 Jun 20;58(1497):81-2 |  Show IntroductionHide Introduction

Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
that binds to the PD-1 receptor, blocking the interaction of PD-1 with its ligands and promoting antitumor ...
The FDA has approved the immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) that highly expresses programmed death-ligand 1 (PD-L1) and has no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations. About 25% of patients with advanced NSCLC have tumors with high levels of PD-L1 expression (PD-L1 expressed on ≥50% of tumor cells). Pembrolizumab was approved earlier for treatment...
Med Lett Drugs Ther. 2017 Jan 30;59(1513):22-3 |  Show IntroductionHide Introduction

Guselkumab (Tremfya) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Nov 06, 2017  (Issue 1533)
— No clinically significant drug interactions have been reported with use of guselkumab, but blocking IL-23 ...
The FDA has approved the interleukin (IL)-23 blocker guselkumab (Tremfya – Janssen) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Guselkumab is the first selective IL-23 blocker to become available in the US.
Med Lett Drugs Ther. 2017 Nov 6;59(1533):179-80 |  Show IntroductionHide Introduction